Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors

Summary

HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the safety/tolerability、the pharmacokinetic profile and efficacy of HS-10365 in Chinese advanced solid tumor patients.

Timeline

Start

2021-11-09

Primary completion

2024-04-30

Completion

2025-12-31

Drugs

Indications